

Title (en)
ANTI-TNFR2 ANTIBODY AND USES THEREOF

Title (de)
ANTI-TNFR2-ANTIKÖRPER UND VERWENDUNGEN DAVON

Title (fr)
ANTICORPS ANTI-TNFR2 ET SES UTILISATIONS

Publication
EP 4367140 A1 20240515 (EN)

Application
EP 22837100 A 20220706

Priority

- US 202163219175 P 20210707
- IB 2022000409 W 20220706

Abstract (en)
[origin: WO2023281313A1] Provided are monoclonal antibodies and antigen-binding fragments thereof specific for TNFR2, and methods of using the same to treat cancer or autoimmune disorder, including combination therapy with antagonists of the PD-1/PD-L1 immune checkpoint.

IPC 8 full level
C07K 16/28 (2006.01); **A61K 39/00** (2006.01); **A61P 35/00** (2006.01); **C12N 15/13** (2006.01)

CPC (source: EP KR)
A61K 39/39 (2013.01 - EP); **A61P 35/00** (2018.01 - EP KR); **C07K 16/2818** (2013.01 - EP KR); **C07K 16/2827** (2013.01 - KR); **C07K 16/2878** (2013.01 - EP KR); **A61K 2039/505** (2013.01 - EP KR); **A61K 2039/507** (2013.01 - EP KR); **C07K 2317/24** (2013.01 - EP KR); **C07K 2317/33** (2013.01 - EP KR); **C07K 2317/34** (2013.01 - EP KR); **C07K 2317/732** (2013.01 - EP KR); **C07K 2317/74** (2013.01 - EP); **C07K 2317/75** (2013.01 - EP KR); **C07K 2317/76** (2013.01 - EP KR); **C07K 2317/90** (2013.01 - EP); **C07K 2317/92** (2013.01 - EP KR)

Designated contracting state (EPC)
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

Designated extension state (EPC)
BA ME

Designated validation state (EPC)
KH MA MD TN

DOCDB simple family (publication)
WO 2023281313 A1 20230112; AR 126387 A1 20231011; AU 2022308421 A1 20240125; CA 3224693 A1 20230112; CN 117980336 A 20240503; EP 4367140 A1 20240515; KR 20240032985 A 20240312; TW 202309096 A 20230301

DOCDB simple family (application)
IB 2022000409 W 20220706; AR P220101767 A 20220706; AU 2022308421 A 20220706; CA 3224693 A 20220706; CN 202280060055 A 20220706; EP 22837100 A 20220706; KR 20247004535 A 20220706; TW 111125395 A 20220706